Two RS’s ago. Geert (former CEO) decided to shift business focus from the platform of dermatology and ophthalmology to now oncology. He made several promises of partnerships and a commercialized retail product for dermatology. To no avail. His failure to execute cost shareholders millions. Stock gets pummeled and after two RS’s drops to 30c. He buys boatloads of cheap shares and retires. Company changes name and collaborates with a European private company that has a cartoon character on the website.
News 
Market Data 
Discover 
